Xbrane Bioscience signs important agreement with global Indian pharmaceutical company
Pressrelease, October 16, 2014
Swedish biotech company Xbrane Bioscience has signed an agreement with a global Indian pharmaceutical company to assist them in developing an optimized production system for a specific Biosimilar (generic protein therapeutic) that will be marketed worldwide. The aim is to help the client reduce production costs in order to gain a competitive advantage in the biosimilar market.
Xbrane has been chosen to help the Indian pharmaceutical company to create an optimal production system that can produce the specific biosimilar with the highest possible yield at the lowest cost. The contract, worth several million SEK, is of significant value and confirms Xbrane’s capabilities and positioning as a trusted contractor and niche expert within the biopharmaceutical industry.
”We see that the biosimilar market is the fastest growing area within the biopharmaceutical market at the moment. With more than 30 branded biologics generating sales of $51bn set to lose patent exclusivity between 2011 and 2015, it is forecasted that the global biosimilar market will have grown from $243m in 2010 to $3.7bn in 2015. Xbrane´s aim is to penetrate the biosimilar market by introducing our unique protein production platform and enabling our clients to keep production costs down which is the main concern amongst the big players in these markets, ” says Siavash Bashiri, CEO of Xbrane Bioscience AB.
During 2014 Xbrane has executed a growth strategy including moving to new research facilities, which enabled the company to recruit additional scientist to the team. The agreement is a direct result of focused efforts aimed at penetrating the biosimilar market in Asia. The next step for Xbrane will be to leverage this contract and its newly acquired Indian network to attract new partnerships in the region.
“We are very happy to have signed this agreement and to get the opportunity to work with and learn from the highly skilled and talented team of the Indian company in our joint efforts to develop a cost efficient protein production system. This will also help us demonstrate our capabilities to future customers and continuing the current partnership with several other products.” says Siavash Bashiri.
About Xbrane Bioscience
Xbrane Bioscience aims to take protein production in E. coli to the next level. By innovative titratable technology and world leading know-how, Xbrane enable its customers to produce their proteins in a controllable system, with higher yields and better quality.
Xbrane was founded in early 2008 in order to commercialize innovations based on research made by Dr. Jan-Willem de Gier and Dr. Samuel Wagner at the Center for Biomembrane Research at the Arrhenius Laboratories at Stockholm University (www.cbr.su.se). Today the company still has extensive collaboration with several academic groups. The company is situated in close proximity to Stockholm University providing access to renowned research expertise and infrastructure